XW143F8Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8

New Technology›Anatomical Regions›Transfusion
  • Billable / Specific Code
ICD-10-PCS XW143F8
CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.FacebookXLinkedInPrint

XW143F8 is a billable ICD-10-PCS procedure code for Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRGs 016, 017. The root operation Transfusion involves putting in blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Administration and transfusion of bone marrow, stem cells, pancreatic islet cells, and t-cells.

Code Identity

ICD-10-PCS Code
XW143F8
Billable Status
Yes — Valid for Submission
Code Describes
Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8
Short Description
Transfuse OTL-103 in Central Vein, Perc, New Tech 8
Parent Code
XW1

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation1Transfusion
4BodyPart4Central Vein
5Approach3Percutaneous
6Device/Substance/TechnologyFOTL-103
7Qualifier8New Technology Group 8

In the ICD-10-PCS Alphabetic Index

These FY 2026 ICD-10-PCS Alphabetic Index entries lead to this code:

OTL-103
Leads to this code's table
Omidubicel
Leads to this code's table
Autotransfusion
Leads to this code's table
New Technology, OTL-103
Leads to this code's table
Atidarsagene Autotemcel
Leads to this code's table
Betibeglogene Autotemcel
Leads to this code's table
Exagamglogene Autotemcel
Leads to this code's table
Mozafancogene Autotemcel
Leads to this code's table
Marnetegragene Autotemcel
Leads to this code's table
New Technology, Omidubicel
Leads to this code's table
Lovotibeglogene Autotemcel
Leads to this code's table
Transfusion, New Technology
Leads to this code's table
Administration, Blood products
Leads to this code's table
Convalescent Plasma (Nonautologous)
Leads to this code's table
Plasma, Convalescent (Nonautologous)
Leads to this code's table

To code new technology of the omidubicel, open the FY 2026 ICD-10-PCS Alphabetic Index at New Technology, then the subterm Omidubicel. The index leads to table XW1, where the approach, Device/Substance/Technology and qualifier values shown in the breakdown above complete the seven-character code XW143F8.

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM011
Administration and transfusion of bone marrow, stem cells, pancreatic islet cells, and t-cells
Clinical domain: Administration of Therapeutic Substances

Code History

Replaces previously assigned code(s):
  • 30243C0 — Transfuse Autol HSPC, Gene Mod in Central Vein, Perc

Similar Procedure Codes

Questions About XW143F8

Is XW143F8 a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW143F8 mean?

The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 1 is the Operation (Transfusion); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character F is the Device/Substance/Technology (OTL-103); the 7th character 8 is the Qualifier (New Technology Group 8).

What MS-DRG does XW143F8 group to?

On an inpatient stay, Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8 maps to MS-DRGs 016, 017, with relative weights from 4.8383 to 5.9297. The MS-DRG sets the fixed Medicare payment for the stay.